Market Overview

UPDATE: Jefferies Raises PT to $18 on ARIAD Pharmaceuticals; Regulatory Catalysts

Related ARIA
Tuesday's Morning Movers: FXCM Takes Another Big Drop
Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 3
3 Biotechs Looking Good this Earnings Season - Earnings ESP (Zacks)

Jefferies raises its price target from $17 to $18 on Buy-rated ARIAD Pharmaceuticals (NASDAQ: ARIA) on regulatory catalysts, despite a wider Q loss.

Jefferies notes, "Wider 1Q net loss of $56M (vs. our est of $39M) largely due to non-cash charge related to warrant liability revaluation. Despite higher OpEx expected in 2012, cash at end-1Q12 of $288M should be sufficient thru 1H13. With regulatory catalysts within next 12 months (ponatinib NDA filing in 3Q12/potential FDA approval early-2013), we believe ARIA is well positioned for meaningful upside."

ARIA closed at $15.91 on Wednesday.

Latest Ratings for ARIA

Dec 2014Credit SuisseDowngradesNeutralUnderperform
Aug 2014CitigroupMaintainsSell
Aug 2014JMP SecuritiesMaintainsMarket Outperform

View More Analyst Ratings for ARIA
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Reiteration Pre-Market Outlook Analyst Ratings


Related Articles (ARIA)

Around the Web, We're Loving...

Get Benzinga's Newsletters